within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01A_AgentsAgainstAmoebiasisAndOtherProtozoalDiseases.P01AB01_Metronidazole;

model Metronidazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.99,
    Cl = 2.5277777777777778e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.00051,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007833333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Metronidazole</td></tr><tr><td>ATC code:</td><td>P01AB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.51</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.13</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Metronidazole is a nitroimidazole antimicrobial agent used to treat infections caused by anaerobic bacteria and certain parasites. It is widely approved and used for conditions such as bacterial vaginosis, trichomoniasis, giardiasis, amebiasis, and infections involving anaerobic bacteria. It is listed as an essential medicine by the World Health Organization.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following single oral dose administration.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Vande Griend, JP, et al., &amp; Linnebur, SA (2012). A year in review: new drugs for older adults in 2011. <i>The American journal of geriatric pharmacotherapy</i> 10(4) 258–263. DOI:<a href=\"https://doi.org/10.1016/j.amjopharm.2012.05.003\">10.1016/j.amjopharm.2012.05.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22682643/\">https://pubmed.ncbi.nlm.nih.gov/22682643</a></p></li><li><p>Carlson, TJ, et al., &amp; Garey, KW (2022). Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. <i>Seminars in respiratory and critical care medicine</i> 43(1) 28–38. DOI:<a href=\"https://doi.org/10.1055/s-0041-1740973\">10.1055/s-0041-1740973</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35172356/\">https://pubmed.ncbi.nlm.nih.gov/35172356</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P01AB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Metronidazole;
